Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.51 |
| ▸ | F2R | P25116 | 12/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538613 | 0.92 | ITGB3 (0.56) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7508440 | 0.90 | ITGB3 (0.52) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7504172 | 0.90 | ITGB3 (0.52) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7446205 | 0.87 | ITGB3 (0.49) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7503218 | 0.85 | ITGB3 (0.51) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7508228 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7442090 | 0.84 | ITGB3 (0.50) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7746749 | 0.84 | ITGB3 (0.56) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7506218 | 0.84 | ITGB3 (0.49) | ITGB3ITGA2BF2RALDH1A1MEN1 | |
| SCHEMBL7445982 | 0.84 | ITGB3 (0.54) | ITGB3ITGA2BF2RALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | ITGB3 423/4885ITGA2B 346/4885F2R 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.